Article of the day, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn:
“Article of the day! Suggest by the Immune Oncology Research Institute.
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Authors: Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost, John R Hyngstrom, Siwen Hu-Lieskovan, Christopher D Lao, Leslie A Fecher, Thach-Giao Truong, Jennifer L Eisenstein, Sunandana Chandra, Jeffrey A Sosman, Kari L Kendra, Richard C Wu, Craig E Devoe, Gary B Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M Reese, Merrick I Ross, Andrew S Poklepovic, Giao Q Phan, Adedayo A Onitilo, Demet G Yasar, Benjamin C Powers, Gary C Doolittle, Gino K In, Niels Kokot, Geoffrey T Gibney, Michael B Atkins, Montaser Shaheen, James A Warneke, Alexandra Ikeguchi, Jose E Najera, Bartosz Chmielowski, Joseph G Crompton, Justin D Floyd, Eddy Hsueh, Kim A Margolin, Warren A Chow, Kenneth F Grossmann, Eliana Dietrich, Victor G Prieto, Michael C Lowe, Elizabeth I Buchbinder, John M Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K Sondak and Antoni Ribas.
Author Affiliations: MD Anderson Cancer Center, SWOG Cancer Research Network ,Cancer Research Consortium of West Michigan ,Rogel Cancer Center ,Huntsman Cancer Institute ,Kaiser Permanente ,USC Norris Comprehensive Cancer Center ,City of Hope ,Cancer Care Specialists of IL ,The Ohio State University ,VCU Massey Comprehensive Cancer Center ,Marshfield Clinic Health System ,The University of Kansas Cancer Center ,MedStar Georgetown University Hospital ,University of Arizona Cancer Center ,Cancer Center of Southwest Oklahoma ,Saint Louis University School of Medicine ,Emory University ,Dana-Farber Cancer Institute ,UPMC Hillman Cancer Center ,Moffitt Cancer Center, et al.”
Source: Immune Oncology Research Institute/LinkedIn
Immune Oncology Research Institute (IMMONC), established in 2022, is a non-profit, independent, patient-centered research institute. The mission of IMMONC is to advance the cancer knowledge and care through breakthrough scientific research, to integrate innovative immune-oncology therapies into the clinical practice for different types of cancers, to generate and collect clinical data for the identification of new therapeutic targets, developing predictive models and optimizing patient outcomes, to increase the availability and accessibility of those discoveries for the cancer patients, to create a world-class professional environment, to attract the brightest minds in cancer field and to train the next generation researchers.